Soligenix Stock Price, News & Analysis (NASDAQ:SNGX)

$2.03 +0.03 (+1.50 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$2.03
Today's Range$2.00 - $2.07
52-Week Range$1.74 - $5.08
Volume30,899 shs
Average Volume32,480 shs
Market Capitalization$17.46 million
P/E Ratio-2.01
Dividend YieldN/A
Beta0.4

About Soligenix (NASDAQ:SNGX)

Soligenix logoSoligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.

Receive SNGX News and Ratings via Email

Sign-up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNGX
CUSIPN/A
Phone609-538-8200

Debt

Debt-to-Equity RatioN/A
Current Ratio2.13%
Quick Ratio2.13%

Price-To-Earnings

Trailing P/E Ratio-2.00990099009901
Forward P/E Ratio-1.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$10.45 million
Price / Sales1.70
Cash FlowN/A
Price / CashN/A
Book Value$1.35 per share
Price / Book1.50

Profitability

Trailing EPS($1.01)
Net Income$-3,240,000.00
Net Margins-90.93%
Return on Equity-112.81%
Return on Assets-71.98%

Miscellaneous

Employees19
Outstanding Shares8,730,000

Soligenix (NASDAQ:SNGX) Frequently Asked Questions

What is Soligenix's stock symbol?

Soligenix trades on the NASDAQ under the ticker symbol "SNGX."

How were Soligenix's earnings last quarter?

Soligenix, Inc. (NASDAQ:SNGX) announced its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.15. The biopharmaceutical company earned $1.82 million during the quarter, compared to analysts' expectations of $1.36 million. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. View Soligenix's Earnings History.

When will Soligenix make its next earnings announcement?

Soligenix is scheduled to release their next quarterly earnings announcement on Monday, March, 26th 2018. View Earnings Estimates for Soligenix.

Where is Soligenix's stock going? Where will Soligenix's stock price be in 2018?

2 brokerages have issued 12-month price objectives for Soligenix's stock. Their predictions range from $2.70 to $5.00. On average, they anticipate Soligenix's stock price to reach $3.85 in the next year. View Analyst Ratings for Soligenix.

Who are some of Soligenix's key competitors?

How do I buy Soligenix stock?

Shares of Soligenix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soligenix's stock price today?

One share of Soligenix stock can currently be purchased for approximately $2.03.

How big of a company is Soligenix?

Soligenix has a market capitalization of $17.46 million and generates $10.45 million in revenue each year. The biopharmaceutical company earns $-3,240,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Soligenix employs 19 workers across the globe.

How can I contact Soligenix?

Soligenix's mailing address is 29 EMMONS DRIVE SUITE C-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]


MarketBeat Community Rating for Soligenix (SNGX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  201
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Soligenix (NASDAQ:SNGX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.503.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.85$5.25$5.25$7.33
Price Target Upside: 73.42% upside118.75% upside172.02% upside259.48% upside

Soligenix (NASDAQ:SNGX) Consensus Price Target History

Price Target History for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ:SNGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/31/2018HC WainwrightDowngradeBuy -> Neutral$5.50 -> $2.70LowView Rating Details
1/3/2018Maxim GroupSet Price TargetBuy$5.00LowView Rating Details
9/7/2016AegisInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Soligenix (NASDAQ:SNGX) Earnings History and Estimates Chart

Earnings by Quarter for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ SNGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/26/2018        
11/6/2017Q3 2017($0.32)($0.17)$1.36 million$1.82 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.32)($0.41)$1.43 million$1.00 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.30)($0.32)$1.30 millionViewN/AView Earnings Details
3/27/2017Q4 2016($0.85)($0.17)$2.90 million$1.70 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.43)$2.50 million$3.00 millionViewN/AView Earnings Details
8/11/2016Q2 2016($0.90)($0.20)$2.50 million$3.16 millionViewN/AView Earnings Details
5/12/2016Q1 2016($0.40)$2.63 millionViewN/AView Earnings Details
3/24/2016Q1($0.06)($0.04)$1.00 million$2.97 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.90)($0.40)$3.00 million$3.90 millionViewN/AView Earnings Details
8/12/2015($0.10)($0.15)$1.00 million$1.10 millionViewN/AView Earnings Details
5/14/2015Q1 2015($1.00)($0.70)$1.50 million$0.82 millionViewN/AView Earnings Details
3/24/2015($0.10)($0.07)$0.80 million$1.93 millionViewN/AView Earnings Details
11/10/2014($0.09)($0.08)$1.51 million$2.79 millionViewN/AView Earnings Details
8/11/2014($0.09)($0.05)$0.80 million$1.40 millionViewN/AView Earnings Details
5/12/2014($0.09)($0.08)$0.80 million$0.90 millionViewN/AView Earnings Details
3/26/2014($0.08)$0.13$0.50 million$1.38 millionViewN/AView Earnings Details
11/12/2013Q3 2013($0.90)($0.90)$0.80 million$0.31 millionViewN/AView Earnings Details
8/12/2013Q2 2013($1.30)($1.70)$0.80 million$0.60 millionViewN/AView Earnings Details
5/3/2013Q1 2013($1.00)$0.90 millionViewN/AView Earnings Details
2/26/2013Q4 2012($0.80)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.70)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.90)ViewN/AView Earnings Details
5/14/2012Q1 2012($1.30)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.85)ViewN/AView Earnings Details
11/14/2011Q3 2011$2.00ViewN/AView Earnings Details
8/12/2011Q2 2011($2.00)($2.00)ViewN/AView Earnings Details
5/13/2011Q1 2011($2.00)($2.00)ViewN/AView Earnings Details
11/12/2010Q3 2010($2.00)($2.00)ViewN/AView Earnings Details
8/13/2010Q2 2010($2.00)($2.00)ViewN/AView Earnings Details
5/17/2010Q1 2010($2.00)ViewN/AView Earnings Details
4/1/2010Q4 2009($2.00)ViewN/AView Earnings Details
11/13/2009Q3 2009($2.00)ViewN/AView Earnings Details
8/14/2009Q2 2009($2.00)ViewN/AView Earnings Details
5/15/2009Q1 2009($2.00)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.60)ViewN/AView Earnings Details
5/16/2008Q1 2008($2.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Soligenix (NASDAQ:SNGX) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.2 EPS
Next Year EPS Consensus Estimate: $-1.4 EPS

Dividends

Dividend History for Soligenix (NASDAQ:SNGX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Soligenix (NASDAQ SNGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.03%
Institutional Ownership Percentage: 2.23%
Insider Trades by Quarter for Soligenix (NASDAQ:SNGX)
Institutional Ownership by Quarter for Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ SNGX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2017Spa EssetifinInsiderBuy293,510$2.12$622,241.20View SEC Filing  
5/8/2017Randal J KirkMajor ShareholderSell160,968$3.12$502,220.16View SEC Filing  
12/16/2016Christopher J SchaberCEOBuy15,804$3.16$49,940.6425,095View SEC Filing  
12/16/2016Marco Maria BrugheraDirectorBuy2,000$3.16$6,320.002,750View SEC Filing  
12/23/2015Jerome B ZeldisDirectorBuy2,500$1.27$3,175.0069,166View SEC Filing  
12/22/2015Christopher J SchaberCEOBuy10,000$1.29$12,900.0085,761View SEC Filing  
12/22/2014Joseph Michael WaruszCFOBuy8,265$1.21$10,000.65View SEC Filing  
6/25/2013Christopher J SchaberCEOBuy9,523$1.05$9,999.15View SEC Filing  
6/25/2013Keith L BrownlieDirectorBuy19,047$1.05$19,999.35View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Soligenix (NASDAQ SNGX) News Headlines

Source:
DateHeadline
Financial Contrast: Trillium Therapeutics (TRIL) & Soligenix (SNGX)Financial Contrast: Trillium Therapeutics (TRIL) & Soligenix (SNGX)
www.americanbankingnews.com - February 5 at 9:46 AM
$1.58 Million in Sales Expected for Soligenix, Inc. (SNGX) This Quarter$1.58 Million in Sales Expected for Soligenix, Inc. (SNGX) This Quarter
www.americanbankingnews.com - February 4 at 6:12 AM
Zacks: Brokerages Anticipate Soligenix, Inc. (SNGX) to Announce -$0.32 EPSZacks: Brokerages Anticipate Soligenix, Inc. (SNGX) to Announce -$0.32 EPS
www.americanbankingnews.com - February 2 at 2:22 PM
Soligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical TrialsSoligenix - Driving Towards Key Inflection Points with Two Pivotal Phase 3 Clinical Trials
www.prnewswire.com - January 25 at 8:02 AM
Windtree Therapeutics (WINT) vs. Soligenix (SNGX) Head-To-Head SurveyWindtree Therapeutics (WINT) vs. Soligenix (SNGX) Head-To-Head Survey
www.americanbankingnews.com - January 18 at 11:18 AM
Head-To-Head Comparison: Soligenix (SNGX) and Osiris Therapeutics (OSIR)Head-To-Head Comparison: Soligenix (SNGX) and Osiris Therapeutics (OSIR)
www.americanbankingnews.com - January 13 at 3:30 AM
Blog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral MucositisBlog Exposure - Soligenix Announced Issuance of US Patent for Use of Dusquetide in Oral Mucositis
finance.yahoo.com - January 4 at 11:01 AM
Maxim Group Reiterates "$5.00" Price Target for Soligenix (SNGX)Maxim Group Reiterates "$5.00" Price Target for Soligenix (SNGX)
www.americanbankingnews.com - January 3 at 8:00 PM
 Analysts Anticipate Soligenix Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million Analysts Anticipate Soligenix Inc. (SNGX) Will Post Quarterly Sales of $1.58 Million
www.americanbankingnews.com - January 1 at 2:38 PM
Zacks: Brokerages Expect Soligenix Inc. (SNGX) Will Post Earnings of -$0.32 Per ShareZacks: Brokerages Expect Soligenix Inc. (SNGX) Will Post Earnings of -$0.32 Per Share
www.americanbankingnews.com - December 30 at 1:16 PM
Critical Contrast: SIGA Technologies (SIGA) & Soligenix (SNGX)Critical Contrast: SIGA Technologies (SIGA) & Soligenix (SNGX)
www.americanbankingnews.com - December 28 at 7:56 PM
Soligenix (SNGX) Stock Rating Reaffirmed by Maxim GroupSoligenix (SNGX) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - December 21 at 4:28 PM
Soligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal RuleSoligenix (SNGX): Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
finance.yahoo.com - December 21 at 3:46 PM
Soligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal RuleSoligenix Identifies Biomarkers for Ricin Toxin Vaccine Testing under the FDA Animal Rule
www.prnewswire.com - December 21 at 6:26 AM
Analyzing Mirati Therapeutics (MRTX) and Soligenix (SNGX)Analyzing Mirati Therapeutics (MRTX) and Soligenix (SNGX)
www.americanbankingnews.com - December 15 at 9:32 PM
Soligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 MillionSoligenix Inc. (SNGX) Expected to Announce Quarterly Sales of $1.58 Million
www.americanbankingnews.com - December 15 at 2:30 PM
Want To Invest In Soligenix Inc (SNGX)? Here’s How It Performed LatelyWant To Invest In Soligenix Inc (SNGX)? Here’s How It Performed Lately
finance.yahoo.com - December 8 at 3:50 PM
Critical Survey: VBI Vaccines (VBIV) versus Soligenix (SNGX)Critical Survey: VBI Vaccines (VBIV) versus Soligenix (SNGX)
www.americanbankingnews.com - December 2 at 9:56 PM
Soligenix Inc. (SNGX) Insider Spa Essetifin Buys 293,510 SharesSoligenix Inc. (SNGX) Insider Spa Essetifin Buys 293,510 Shares
www.americanbankingnews.com - December 1 at 9:02 PM
Soligenix (SNGX) and ContraFect (CFRX) Head-To-Head ContrastSoligenix (SNGX) and ContraFect (CFRX) Head-To-Head Contrast
www.americanbankingnews.com - November 30 at 3:12 AM
Soligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CASoligenix Announces Presentation and Poster at the 2017 Chemical and Biological Defense Science and Technology Conference in Long Beach, CA
finance.yahoo.com - November 27 at 4:13 PM
$1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter$1.58 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter
www.americanbankingnews.com - November 27 at 8:11 AM
Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX)Head-To-Head Survey: Soligenix (SNGX) vs. Mirati Therapeutics (MRTX)
www.americanbankingnews.com - November 26 at 1:16 AM
Critical Survey: Soligenix (SNGX) vs. TetraLogic Pharmaceuticals Corporation (TLOG)Critical Survey: Soligenix (SNGX) vs. TetraLogic Pharmaceuticals Corporation (TLOG)
www.americanbankingnews.com - November 23 at 5:46 AM
Analyzing XOMA Corporation (XOMA) and Soligenix (SNGX)Analyzing XOMA Corporation (XOMA) and Soligenix (SNGX)
www.americanbankingnews.com - November 19 at 5:22 AM
Who Owns Most Of Soligenix Inc (SNGX)?Who Owns Most Of Soligenix Inc (SNGX)?
finance.yahoo.com - November 15 at 10:06 AM
Zacks Investment Research Research Analysts Increase Earnings Estimates for Soligenix Inc. (SNGX)Zacks Investment Research Research Analysts Increase Earnings Estimates for Soligenix Inc. (SNGX)
www.americanbankingnews.com - November 9 at 7:21 AM
Soligenix Inc. (SNGX) Expected to Post Quarterly Sales of $1.36 MillionSoligenix Inc. (SNGX) Expected to Post Quarterly Sales of $1.36 Million
www.americanbankingnews.com - November 8 at 4:50 AM
Soligenix Inc. (SNGX) Posts Quarterly  Earnings Results, Beats Estimates By $0.15 EPSSoligenix Inc. (SNGX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - November 7 at 9:06 AM
-$0.40 EPS Expected for Soligenix Inc. (SNGX) This Quarter-$0.40 EPS Expected for Soligenix Inc. (SNGX) This Quarter
www.americanbankingnews.com - November 6 at 7:32 PM
Soligenix Inc. (SNGX) Stock Rating Reaffirmed by HC WainwrightSoligenix Inc. (SNGX) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 6 at 11:38 AM
Soligenix Inc. (SNGX) Earns Buy Rating from HC WainwrightSoligenix Inc. (SNGX) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 6 at 11:38 AM
Soligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above MarketSoligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market
finance.yahoo.com - November 4 at 4:05 PM
Analyzing Grifols, (GRFS) and Soligenix (SNGX)Analyzing Grifols, (GRFS) and Soligenix (SNGX)
www.americanbankingnews.com - November 3 at 3:18 AM
Soligenix Inc. (SNGX) PT Set at $5.00 by Maxim GroupSoligenix Inc. (SNGX) PT Set at $5.00 by Maxim Group
www.americanbankingnews.com - October 31 at 2:07 PM
Soligenix Inc. (SNGX) Given a $5.00 Price Target by Maxim Group AnalystsSoligenix Inc. (SNGX) Given a $5.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - October 24 at 7:26 PM
$1.36 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter$1.36 Million in Sales Expected for Soligenix Inc. (SNGX) This Quarter
www.americanbankingnews.com - October 20 at 2:02 PM
 Brokerages Anticipate Soligenix, Inc. (SNGX) to Post -$0.40 Earnings Per Share Brokerages Anticipate Soligenix, Inc. (SNGX) to Post -$0.40 Earnings Per Share
www.americanbankingnews.com - October 18 at 4:08 AM
Head-To-Head Survey: Soligenix (SNGX) vs. The CompetitionHead-To-Head Survey: Soligenix (SNGX) vs. The Competition
www.americanbankingnews.com - October 6 at 2:06 AM
Contrasting Epirus Biopharmaceuticals (EPRS) and Soligenix (SNGX)Contrasting Epirus Biopharmaceuticals (EPRS) and Soligenix (SNGX)
www.americanbankingnews.com - October 4 at 2:40 PM
Critical Contrast: Soligenix (SNGX) & The CompetitionCritical Contrast: Soligenix (SNGX) & The Competition
www.americanbankingnews.com - September 30 at 6:26 AM
Head-To-Head Survey: Soligenix (SNGX) vs. Its CompetitorsHead-To-Head Survey: Soligenix (SNGX) vs. Its Competitors
www.americanbankingnews.com - September 30 at 12:30 AM
Comparing Soligenix (SNGX) & The CompetitionComparing Soligenix (SNGX) & The Competition
www.americanbankingnews.com - September 27 at 10:12 AM
Soligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine CandidateSoligenix Announces $700,000 Subaward Supporting Development Collaboration on Thermostabilization of an Ebola Vaccine Candidate
finance.yahoo.com - September 27 at 8:44 AM
Financial Survey: Soligenix (SNGX) vs. Senesco Technologies (SVON)Financial Survey: Soligenix (SNGX) vs. Senesco Technologies (SVON)
www.americanbankingnews.com - September 23 at 10:28 PM
Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017Soligenix, Inc. :SNGX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 23 at 7:31 AM
Soligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III TrialsSoligenix (SNGX): Two SBIR Grant Awarded Supporting Two Pivotal Phase III Trials
finance.yahoo.com - September 23 at 7:31 AM
HC Wainwright Reaffirms Buy Rating for Soligenix Inc. (SNGX)HC Wainwright Reaffirms Buy Rating for Soligenix Inc. (SNGX)
www.americanbankingnews.com - September 21 at 5:39 PM
Maxim Group Reaffirms "Buy" Rating for Soligenix Inc. (SNGX)Maxim Group Reaffirms "Buy" Rating for Soligenix Inc. (SNGX)
www.americanbankingnews.com - September 20 at 9:46 AM
Soligenix (SNGX) versus Aevi Genomic Medicine (GNMX) Critical ContrastSoligenix (SNGX) versus Aevi Genomic Medicine (GNMX) Critical Contrast
www.americanbankingnews.com - September 18 at 2:26 AM

SEC Filings

Soligenix (NASDAQ:SNGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Soligenix (NASDAQ:SNGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Soligenix (NASDAQ SNGX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.